Form 4: Seres Therapeutics Executive VP Teresa Young Reports Stock Transactions

Teresa Young, EVP of Seres Therapeutics, reports the vesting and selling of restricted stock units to cover taxes, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Teresa L. Young, EVP of Seres Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On May 15, 2025, Young acquired 133 shares of common stock through the vesting of restricted stock units (RSUs) and another 98 shares through the vesting of additional RSUs.
• On May 16, 2025, Young sold 63 shares of common stock at a price of $7.28 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2023, to cover taxes associated with the vesting of the RSUs.
• The reported transactions reflect a 1-for-20 reverse stock split that occurred on April 21, 2025.
• Following the reported transactions, Young beneficially owns 5,044 shares of common stock and holds derivative securities including 929 and 1,073 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are routine and pre-planned, primarily for tax purposes. No indication of significant concern or excitement.

Positives

• The transactions are part of a pre-arranged Rule 10b5-1 trading plan, indicating transparency and compliance.
• The vesting of RSUs suggests continued employment and alignment with the company's long-term success.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it's part of a pre-defined plan.

Risks

• Executive stock sales, even for tax obligations, can sometimes create short-term price volatility.
• Continued reliance on stock-based compensation may dilute existing shareholders over time.

Future Outlook

The remaining restricted stock units will continue to vest and settle in 12 equal quarterly installments.

Industry Context

Executive stock transactions are common in publicly traded companies, often tied to compensation packages and vesting schedules. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages including RSUs are standard practice in the biotechnology industry, similar to companies like Biogen (BIIB) and Gilead Sciences (GILD).
• The use of Rule 10b5-1 trading plans is a common strategy among executives to manage stock sales in a compliant manner, mirroring practices seen at companies like Amgen (AMGN) and Regeneron (REGN).

Stakeholder Impact

• The stock sale may have a minor short-term impact on shareholders due to increased selling pressure.
• Employees holding RSUs are likely to be interested in the stock price and vesting schedule.

Key Dates

Keywords

Seres Therapeutics, MCRB, Form 4, Teresa Young, Stock Sale, RSU, Rule 10b5-1, Beneficial Ownership, Reverse Stock Split